Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2293 | Matched Placebo Hydroxychloroquine Wiki | 1.00 |
| drug6 | 0.12% Chlorhexidine Gluconate Wiki | 1.00 |
| drug5 | 0.075% Cetylpyridinium Chloride Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Randomized, double-blind prospective trial to test the efficacy and acceptability of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 480 subject participants and one, 75-90 minute visit.
Description: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 15 Minutes Time: Baseline, 15 minutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 30 Minutes Time: Baseline, 30 MinutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 45 Minutes Time: Baseline, 45 MinutesDescription: Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID+ patient saliva
Measure: Change in Quantitative Polymerase Chain Reaction (qPCR) from Baseline to 60 Minutes Time: Baseline, 60 MinutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports